Amylyx Pharmaceuticals Files Q1 2025 10-Q
Ticker: AMLX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1658551
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials, drug-development
TL;DR
Amylyx Q1 10-Q is in: check financials and pipeline updates.
AI Summary
Amylyx Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and operations, including details on its product candidates like AMX0035 ALS and Avexitide. The filing also covers events such as an underwritten public offering on January 13, 2025, and provides balance sheet information as of March 31, 2025.
Why It Matters
This filing provides investors with a quarterly update on Amylyx's financial health and operational progress, including key financial metrics and disclosures about their drug development pipeline.
Risk Assessment
Risk Level: medium — Biotech companies like Amylyx face inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Balance Sheet Date (Key date for financial reporting)
- 2025-01-01 to 2025-03-31 — Reporting Period (First quarter of 2025)
- 2024-01-01 to 2024-03-31 — Prior Year Period (First quarter of 2024 for comparison)
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report for the 10-Q
- 43 THORNDIKE STREET, CAMBRIDGE, MA 02141 (address) — Company's business and mailing address
- AMX0035 ALS (product) — Product candidate mentioned in operating segments
- Avexitide (product) — Product candidate mentioned in operating segments
- 20250113 (date) — Date of an underwritten public offering
FAQ
What were Amylyx's total revenues for the first quarter of 2025?
The filing does not explicitly state total revenues for Q1 2025 in the provided text snippet, but it does mention operating segments and expenses for the period.
What is the status of AMX0035 ALS and Avexitide as of March 31, 2025?
The filing indicates that AMX0035 ALS and Avexitide are part of the company's operating segments for the period of January 1, 2025, to March 31, 2025, suggesting ongoing development or commercialization efforts.
Did Amylyx conduct any public offerings in early 2025?
Yes, the filing notes an underwritten public offering occurred on January 13, 2025.
What is Amylyx's fiscal year end?
Amylyx's fiscal year ends on December 31.
What is the company's primary business classification?
Amylyx Pharmaceuticals, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Amylyx Pharmaceuticals, Inc. (AMLX).